These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 25993203)

  • 81. Development and Challenges of the Discovery of HER2 Inhibitors.
    Sun ZG; Zhao LH; Li ZN; Zhu HL
    Mini Rev Med Chem; 2020; 20(20):2123-2134. PubMed ID: 32727326
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer.
    Moulder SL; Craft BS; Hortobagyi GN
    Anticancer Agents Med Chem; 2008 Jun; 8(5):481-7. PubMed ID: 18537531
    [TBL] [Abstract][Full Text] [Related]  

  • 83. HER2-directed treatment of metastatic breast cancer: unanswered questions.
    Rao R; Cobleigh M
    Oncology (Williston Park); 2013 Mar; 27(3):176, 178, 180. PubMed ID: 23687785
    [No Abstract]   [Full Text] [Related]  

  • 84. How can we optimize treatment of HER2-positive metastatic breast cancer?
    Hamilton EP; Blackwell KL
    Oncology (Williston Park); 2013 Mar; 27(3):180, 182. PubMed ID: 23687786
    [No Abstract]   [Full Text] [Related]  

  • 85. Adjuvant and neoadjuvant therapy for breast cancer.
    Shien T; Iwata H
    Jpn J Clin Oncol; 2020 Mar; 50(3):225-229. PubMed ID: 32147701
    [TBL] [Abstract][Full Text] [Related]  

  • 86. HER2-Targeted Therapy in Osteosarcoma.
    Gill J; Hingorani P; Roth M; Gorlick R
    Adv Exp Med Biol; 2020; 1257():55-66. PubMed ID: 32483730
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here.
    Rugo HS
    Oncology (Williston Park); 2012 Jan; 26(1):26, 28-9. PubMed ID: 22393793
    [No Abstract]   [Full Text] [Related]  

  • 88. Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management.
    Mahtani R; Hineman L
    J Adv Pract Oncol; 2019 Mar; 10(2):136-153. PubMed ID: 31538025
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Adrenal crisis in metastatic breast cancer.
    Doleschal B; Petzer A; Aichberger KJ
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28687693
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Optimizing (neo)adjuvant treatment of HER2-positive breast cancer.
    Basho RK; McArthur HL
    Ther Adv Med Oncol; 2018; 10():1758835918775697. PubMed ID: 30034547
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Highlights in breast cancer from ASCO 2016.
    Cardoso F
    ESMO Open; 2016; 1(5):e000106. PubMed ID: 27900208
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Paradigm change in urological, gynaecological and breast cancer management: A new practice-changing data from ASCO 2022 annual meeting.
    Andrif M; Elmarrachi H; Ismaili N
    Cancer Treat Res Commun; 2023; 35():100677. PubMed ID: 36696853
    [TBL] [Abstract][Full Text] [Related]  

  • 93. An update into the pathophysiological role of HER2 in cancer: therapeutic implications.
    Ocaña A; Pandiella A
    Clin Transl Oncol; 2007 Sep; 9(9):543-4. PubMed ID: 17921099
    [No Abstract]   [Full Text] [Related]  

  • 94. Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review.
    Kyriazoglou A; Kaparelou M; Goumas G; Liontos M; Zakopoulou R; Zografos E; Zygogianni A; Dimopoulos MA; Zagouri F
    Breast Care (Basel); 2022 Feb; 17(1):63-70. PubMed ID: 35355696
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Targeted Therapy: Can It Substitute for Chemotherapy?
    Schütz F
    Breast Care (Basel); 2008; 3(4):257-261. PubMed ID: 21076606
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Update Breast Cancer 2017 - Implementation of Novel Therapies.
    Lux MP; Janni W; Hartkopf AD; Nabieva N; Taran FA; Overkamp F; Kolberg HC; Hadji P; Tesch H; Ettl J; Huober JB; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A; Fasching PA
    Geburtshilfe Frauenheilkd; 2017 Dec; 77(12):1281-1290. PubMed ID: 29269955
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
    Yu Q; Zhu Z; Liu Y; Zhang J; Li K
    PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.
    Grassadonia A; Caporale M; Tinari N; Zilli M; DeTursi M; Gamucci T; Vici P; Natoli C
    J Cancer; 2015; 6(6):575-82. PubMed ID: 26000050
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report.
    Miranda Romero P; Marín Gil R
    Farm Hosp; 2015 May; 39(3):171-5. PubMed ID: 26005893
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Optimizing Treatment of HER2-Positive Breast Cancer.
    Gradishar WJ
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):649-51. PubMed ID: 25995420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.